微质衍生的纳米纤维同步宏观自和伴侣介导的自,用于阿尔茨海默氏症治疗
Min Li1, Shuang Chen1, Rong Guo2
1Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, PR China.
Signal transduction and targeted therapy
|November 3, 2025
概括
研究人员开发了一种新的纳米微粒输送系统 (AR@ENV),在阿尔茨海默病 (AD) 模型中同时激活宏自和伴侣介导自 (CMA),有效清除有毒聚合物并改善认知功能.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自,包括宏自和伴侣介导自 (CMA),在阿尔茨海默氏症 (AD) 中是失调的.
- 损坏的自促使AD中有毒蛋白质聚合物的积累.
- 血脑屏障 (BBB) 限制了针对大脑自的治疗策略.
研究的目的:
- 为了调查双自道损伤在AD病变发生过程中的作用.
- 开发一种新的药物递送系统,在BBB中同时激活宏自和CMA.
- 在AD小鼠模型中评估这种双激活策略的治疗疗效.
主要方法:
- 开发微质-脂质体融合挤出 (MiLi-FE) 技术,以制造微质衍生的纳米纤维 (AR@ENV).
- 通过AR@ENV.通过AR@ENV传递AR7 (CMA诱导剂) 和拉巴胺素 (宏自诱导剂) 的代码传递.
- 在AD小鼠模型中评估AR@ENV的BBB透,神经元吸收和治疗效果.
主要成果:
- AR@ENV有效地穿越BBB,并针对AD大脑病理.
- 通过AR@ENV同步激活CMA和宏自,增强β-粉样和有毒聚合物的清除.
- 该治疗恢复了蛋白质稳定,减少了神经炎症,并拯救了AD小鼠的认知缺陷.
- 该MiLi-FE平台证明了对中枢神经系统药物输送的多功能性.
结论:
- 通过AR@ENV对自途径进行有针对性,双重激活是阿尔茨海默病的一种有前途的治疗策略.
- 该MiLi-FE平台提供了一个可扩展的方法来治疗神经系统疾病,通过使中枢神经系统药物输送.
- 这种方法解决了自调节疗法BBB透的局限性.
更多相关视频
相关概念视频
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


